JP7763450B2 - 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 - Google Patents

免疫療法に関するオルガノイドならびにそれを調製および使用する方法

Info

Publication number
JP7763450B2
JP7763450B2 JP2020540738A JP2020540738A JP7763450B2 JP 7763450 B2 JP7763450 B2 JP 7763450B2 JP 2020540738 A JP2020540738 A JP 2020540738A JP 2020540738 A JP2020540738 A JP 2020540738A JP 7763450 B2 JP7763450 B2 JP 7763450B2
Authority
JP
Japan
Prior art keywords
cells
tumor
organoids
immune
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020540738A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511790A (ja
JP2021511790A5 (https=
Inventor
アレクサンダー スカーダル
コンスタンティノス ヴォタノポーロス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wake Forest University Health Sciences
Original Assignee
Wake Forest University Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wake Forest University Health Sciences filed Critical Wake Forest University Health Sciences
Publication of JP2021511790A publication Critical patent/JP2021511790A/ja
Publication of JP2021511790A5 publication Critical patent/JP2021511790A5/ja
Priority to JP2023118838A priority Critical patent/JP2023139153A/ja
Priority to JP2025125610A priority patent/JP2025172735A/ja
Application granted granted Critical
Publication of JP7763450B2 publication Critical patent/JP7763450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
    • G06V20/698—Matching; Classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Multimedia (AREA)
JP2020540738A 2018-02-02 2019-02-01 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 Active JP7763450B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023118838A JP2023139153A (ja) 2018-02-02 2023-07-21 免疫療法に関するオルガノイドならびにそれを調製および使用する方法
JP2025125610A JP2025172735A (ja) 2018-02-02 2025-07-28 免疫療法に関するオルガノイドならびにそれを調製および使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625628P 2018-02-02 2018-02-02
US62/625,628 2018-02-02
PCT/US2019/016236 WO2019152767A1 (en) 2018-02-02 2019-02-01 Organoids related to immunotherapy and methods of preparing and using the same

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023118838A Division JP2023139153A (ja) 2018-02-02 2023-07-21 免疫療法に関するオルガノイドならびにそれを調製および使用する方法
JP2025125610A Division JP2025172735A (ja) 2018-02-02 2025-07-28 免疫療法に関するオルガノイドならびにそれを調製および使用する方法

Publications (3)

Publication Number Publication Date
JP2021511790A JP2021511790A (ja) 2021-05-13
JP2021511790A5 JP2021511790A5 (https=) 2022-01-21
JP7763450B2 true JP7763450B2 (ja) 2025-11-04

Family

ID=67478724

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020540738A Active JP7763450B2 (ja) 2018-02-02 2019-02-01 免疫療法に関するオルガノイドならびにそれを調製および使用する方法
JP2023118838A Pending JP2023139153A (ja) 2018-02-02 2023-07-21 免疫療法に関するオルガノイドならびにそれを調製および使用する方法
JP2025125610A Pending JP2025172735A (ja) 2018-02-02 2025-07-28 免疫療法に関するオルガノイドならびにそれを調製および使用する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023118838A Pending JP2023139153A (ja) 2018-02-02 2023-07-21 免疫療法に関するオルガノイドならびにそれを調製および使用する方法
JP2025125610A Pending JP2025172735A (ja) 2018-02-02 2025-07-28 免疫療法に関するオルガノイドならびにそれを調製および使用する方法

Country Status (7)

Country Link
US (2) US12038432B2 (https=)
EP (1) EP3746785A4 (https=)
JP (3) JP7763450B2 (https=)
KR (1) KR102820005B1 (https=)
AU (1) AU2019215096B2 (https=)
CA (1) CA3089127A1 (https=)
WO (1) WO2019152767A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016331081B2 (en) 2015-10-02 2021-04-29 Wake Forest University Health Sciences Methods and apparatus for modeling cancer metastasis in vitro
US11959095B2 (en) 2016-10-14 2024-04-16 Wake Forest University Health Sciences Compositions, cell constructs, and methods of making and using the same
US11286231B2 (en) 2016-10-26 2022-03-29 Wake Forest University Health Sciences Hydrogen-bonding compounds, compositions comprising the same, and methods of preparing and using the same
US11629329B2 (en) 2017-10-11 2023-04-18 Wake Forest University Health Sciences Bioink compositions and methods of preparing and using the same
US12038432B2 (en) 2018-02-02 2024-07-16 Wake Forest University Health Sciences Organoids related to immunotherapy and methods of preparing and using the same
US11993785B2 (en) 2018-08-07 2024-05-28 Wake Forest University Health Sciences Immersion deposition methods and compositions for use in the same
US11213608B2 (en) 2018-08-14 2022-01-04 Wake Forest University Health Sciences Compositions including gelatin nanoparticles and methods of use thereof
WO2021081253A1 (en) 2019-10-22 2021-04-29 Tempus Labs, Inc. Systems and methods for predicting therapeutic sensitivity
EP4070232A4 (en) 2019-12-05 2024-01-31 Tempus Labs, Inc. SYSTEMS AND METHODS FOR HIGH-THROUGHPUT ACTIVE SCREENING
US11561178B2 (en) 2020-04-20 2023-01-24 Tempus Labs, Inc. Artificial fluorescent image systems and methods
JP2023550651A (ja) * 2020-11-24 2023-12-04 デューク ユニバーシティ 液滴オルガノイドに基づく癌免疫学アッセイ及び其れを使用する方法
US20240110155A1 (en) * 2020-12-17 2024-04-04 Genome Biologics Ug A dual cardiac-blood model system for disease modelling and drug screening
WO2022154754A1 (en) * 2021-01-15 2022-07-21 Nanyang Technological University Core-shell microspheres
EP4060552B1 (en) * 2021-03-15 2025-02-26 Universiteit Antwerpen Label-free analysis of brightfield microscope images
JP2024534463A (ja) * 2021-09-15 2024-09-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー オルガノイドを使用して腫瘍反応性免疫集団を増幅する方法
KR102511632B1 (ko) * 2022-07-26 2023-03-20 오가노이드사이언스 주식회사 암 오가노이드 및 til 포함 종양 미세환경을 이용한 항암제 효능 평가 방법
KR102511633B1 (ko) * 2022-08-09 2023-03-20 오가노이드사이언스 주식회사 M1 마크로파지 및 m2 마크로파지 혼합물을 이용한 항암제 효능 평가 방법
WO2023043278A1 (ko) * 2021-09-17 2023-03-23 오가노이드사이언스 주식회사 항암제 효능 평가 또는 스크리닝 방법
KR102527906B1 (ko) * 2022-07-29 2023-05-02 오가노이드사이언스 주식회사 수지상 세포의 약물 효능평가 용도
KR102527911B1 (ko) * 2022-08-02 2023-05-02 오가노이드사이언스 주식회사 조절 t 세포의 약물 스크리닝 용도
CN115521898A (zh) * 2021-11-04 2022-12-27 上海万何圆生物科技有限公司 肝癌类器官与nk细胞共培养的免疫细胞治疗方法及应用
CN115521912A (zh) * 2021-11-04 2022-12-27 上海万何圆生物科技有限公司 一种以类器官与t细胞共培养的免疫细胞治疗方法及应用
CN115537395A (zh) * 2021-11-04 2022-12-30 上海万何圆生物科技有限公司 一种肝癌类器官与TILs细胞共培养的治疗方法及其应用
KR102818207B1 (ko) * 2022-02-10 2025-06-12 가톨릭대학교 산학협력단 환자 유래 뇌수막종 오가노이드 및 이의 제조 방법
TWI825620B (zh) * 2022-03-14 2023-12-11 國立清華大學 細胞分選方法
WO2024151779A1 (en) * 2023-01-10 2024-07-18 Georgia Tech Research Corporation In vitro platform for cell sorting
KR102952410B1 (ko) * 2023-01-20 2026-04-14 에스지바이오사이언스 주식회사 육종 튜머로이드 제조 방법 및 그의 용도
WO2025070382A1 (ja) * 2023-09-25 2025-04-03 武田薬品工業株式会社 アッセイ方法
WO2025085577A1 (en) * 2023-10-17 2025-04-24 NetNoids Rx Laboratories, LLC Compositions and methods for accelerating development of cancer therapeutics
CN117511880B (zh) * 2024-01-08 2024-04-19 北京大橡科技有限公司 肿瘤体外原位模型的构建方法、培养基及体外应用
CN118006555B (zh) * 2024-04-10 2024-06-25 北京市肿瘤防治研究所 一种黑色素瘤类器官培养基及其用途
CN119851750A (zh) * 2025-03-19 2025-04-18 华中科技大学同济医学院附属同济医院 肝脏类器官的药物筛选和疾病模型构建的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519360A (ja) 2010-02-11 2013-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ３ｄａｄｃｃｎｋｆａｃｓアッセイ

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734372A (en) 1983-02-04 1988-03-29 Brown University Research Foundation Cell culturing methods and apparatus
ATE374034T1 (de) 1996-04-03 2007-10-15 Rogosin Inst Konditioniertes medium und diffusionsfähiges biologisches material gewonnen durch inkubierung von eingeschlossenen zellen
US6224912B1 (en) 1996-04-03 2001-05-01 The Rogo Institute Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
AU2685699A (en) 1998-02-18 1999-09-06 Cell Based Delivery Methods of screening compounds for bioactivity in organized tissue
FR2791505B1 (fr) 1999-03-25 2001-06-08 Inside Technologies Decodeur bpsk synchrone
CA2497343C (en) 2001-08-14 2013-04-02 Washington University In St. Louis Systems and methods for screening pharmaceutical chemicals
JP2006503080A (ja) 2002-10-11 2006-01-26 ノボセル インコーポレイテッド 疾患治療用のカプセルで包んだ生物材料の移植
WO2005050200A2 (en) 2003-11-13 2005-06-02 Genentech, Inc. Screening assays and methods of tumor treatment
US8298824B2 (en) * 2004-04-28 2012-10-30 Sanofi Pasteur Vaxdesign Corporation Methods of evaluating a test agent in a diseased cell model
US20060141620A1 (en) 2004-11-15 2006-06-29 The Regents Of The University Of Michigan System and method for forming a cardiac tissue construct
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
WO2007095192A2 (en) 2006-02-10 2007-08-23 Tengion Inc. Bioreactor for organ reconstruction and augmentation
EP2004328B1 (en) 2006-03-09 2014-06-04 Agency for Science, Technology and Research Method for performing a reaction in a droplet
JP5024777B2 (ja) 2006-03-14 2012-09-12 独立行政法人農業・食品産業技術総合研究機構 細胞動態の観察装置
JP2008054521A (ja) 2006-08-29 2008-03-13 Canon Inc 細胞培養処理装置及び細胞培養処理方法
WO2008147428A1 (en) 2006-10-05 2008-12-04 Nanopoint, Inc. Systems and methods for active microfluidic cell handling
FR2917293B1 (fr) 2007-06-13 2010-11-26 Olivier Paul Christian Schussler Support collagenique modifie par greffage covalent de molecules d'adhesion : procedes et applications pour l'ingenierie de tissu contractile, la therapie cellulaire en thoracique et cardiovasculaire
US20090076584A1 (en) 2007-09-19 2009-03-19 Xtent, Inc. Apparatus and methods for deployment of multiple custom-length prostheses
WO2009146911A2 (en) 2008-06-04 2009-12-10 Uwe Marx Organ-on-a-chip-device
IT1392820B1 (it) 2008-08-06 2012-03-23 Dominici Dispositivo per la coltura di cellule
GB0815428D0 (en) 2008-08-22 2008-10-01 Capsant Neurotechnologies S A Method
US8748180B2 (en) 2009-07-29 2014-06-10 Cornell University Microfluidic device for pharmacokinetic-pharmacodynamic study of drugs and uses thereof
WO2011085225A1 (en) 2010-01-08 2011-07-14 Wake Forest University Health Sciences Delivery system
EP2523656A4 (en) 2010-01-15 2013-12-11 Univ Utah Res Found RETICULATED HYDROGELS AND METHODS OF MAKING AND USING THE SAME
CA2807438C (en) 2010-08-06 2020-09-01 Technische Universitaet Berlin Self-contained circulation system and method of use thereof
US20120089238A1 (en) 2010-10-06 2012-04-12 Hyun-Wook Kang Integrated organ and tissue printing methods, system and apparatus
WO2013040559A1 (en) 2011-09-16 2013-03-21 Wake Forest University Health Sciences Fabrication of gelatin hydrogel sheet for the transplantation of corneal endothelium
US9725687B2 (en) 2011-12-09 2017-08-08 President And Fellows Of Harvard College Integrated human organ-on-chip microphysiological systems
US10087422B2 (en) 2011-12-09 2018-10-02 President And Fellows Of Harvard College Organ chips and uses thereof
US9857356B2 (en) 2011-12-09 2018-01-02 President And Fellows Of Havard College Muscle chips and methods of use thereof
CN113699105A (zh) 2011-12-23 2021-11-26 人类起源公司 包含脱细胞并再群体化的胎盘血管支架的类器官
JP2014033626A (ja) 2012-08-08 2014-02-24 Juntendo ヒト癌上皮細胞の遠隔転移のモデルマウス作出方法
EP2897625B1 (en) 2012-09-10 2019-10-23 Wake Forest University Health Sciences Amniotic membrane and its use in wound healing and tissue engineering constructs
DK2712918T3 (en) 2012-09-28 2015-02-16 Tissuse Gmbh Multi-organ-chip with improved lifetime and homeostasis
EP2716751A1 (en) 2012-10-08 2014-04-09 BioTime, Inc. Differentiated progeny of clonal progenitor cell lines
WO2014127250A1 (en) 2013-02-14 2014-08-21 Cfd Research Corporation Cell culture device with an array of microfluidic networks
US20150079584A1 (en) 2013-03-15 2015-03-19 Kiyatec Inc. Bioreactor system
US9460931B2 (en) 2013-09-17 2016-10-04 Sandisk Technologies Llc High aspect ratio memory hole channel contact formation
US9587221B2 (en) 2013-11-11 2017-03-07 Auburn University Encapsulation and cardiac differentiation of hiPSCs in 3D PEG-fibrinogen hydrogels
BR112016016635A2 (pt) 2014-01-22 2017-08-08 Zpredicta Inc Método e aparelho para isolar células invasivas e metastáticas para avaliação terapêutica e previsão de capacidade metastática
JP6284147B2 (ja) 2014-03-07 2018-02-28 国立研究開発法人産業技術総合研究所 乳癌の骨髄高転移性マウス乳癌細胞株の樹立方法
EP3808838B1 (en) 2014-04-04 2024-04-10 Organovo, Inc. Engineered three-dimensional breast tissue, adipose tissue, and tumor disease model
US10473646B2 (en) * 2014-05-26 2019-11-12 Universitaetsspital Basel In vitro culturing or expanding human or animal tissue
WO2016049363A1 (en) 2014-09-24 2016-03-31 Los Alamos National Security, Llc Bio-assessment device and method of making the device
CA3191977A1 (en) 2014-10-24 2016-04-28 Wake Forest University Health Sciences Tissue-mimicking hydrogel compositions for biofabrication
WO2016081554A1 (en) * 2014-11-18 2016-05-26 Neostem Oncology, Llc Immunogenic compositions prepared from tumor cells derived from peripheral blood and originating from a solid tumor and their use
WO2016100227A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Multi-organ cell culture system and methods of use thereof
AU2016331081B2 (en) * 2015-10-02 2021-04-29 Wake Forest University Health Sciences Methods and apparatus for modeling cancer metastasis in vitro
US20180273904A1 (en) 2015-10-02 2018-09-27 Wake Forest University Health Sciences Spontaneously beating cardiac organoid constructs and integrated body-on-chip apparatus containing the same
WO2017070007A2 (en) 2015-10-15 2017-04-27 Wake Forest University Health Sciences Methods of producing in vitro liver constructs and uses thereof
US10993433B2 (en) 2015-10-15 2021-05-04 Wake Forest University Health Sciences Method of producing in vitro testicular constructs and uses thereof
EP3362554B1 (en) 2015-10-16 2025-09-03 Wake Forest University Health Sciences Multi-layer airway organoids and methods of making and using the same
US11371000B2 (en) 2016-03-30 2022-06-28 EMULATE, Inc. Devices, systems and methods for inhibiting invasion and metastases of cancer
KR20180133442A (ko) 2016-04-13 2018-12-14 비비아 바이오테크 에스.엘. 생체외 bite 활성화된 t 세포
US11760977B2 (en) 2016-05-25 2023-09-19 Salk Institute For Biological Studies Compositions and methods for organoid generation and disease modeling
US10766970B2 (en) 2016-07-01 2020-09-08 Wake Forest University Health Sciences Modified carbohydrates, compositions comprising the same, and methods of making and using the same
US20180000743A1 (en) 2016-07-01 2018-01-04 Wake Forest University Modified Alginate Hydrogels for Therapeutic Agents, their Preparation and Methods Thereof
WO2018013589A1 (en) * 2016-07-12 2018-01-18 Flagship Pioneering, Inc. Methods and compositions for thymic transplantation
KR20250017294A (ko) 2016-08-03 2025-02-04 웨이크 포리스트 유니버시티 헬스 사이언시즈 암 모델링 플랫폼 및 그를 사용하는 방법
US11959095B2 (en) 2016-10-14 2024-04-16 Wake Forest University Health Sciences Compositions, cell constructs, and methods of making and using the same
EP4253956A3 (en) 2016-10-14 2023-12-06 Wake Forest University Health Sciences Multi-organ "body on a chip" apparatus utilizing a common media
US11286231B2 (en) 2016-10-26 2022-03-29 Wake Forest University Health Sciences Hydrogen-bonding compounds, compositions comprising the same, and methods of preparing and using the same
US11180735B2 (en) * 2016-10-28 2021-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods to preserve tumor-stromal interactions in culture and therapeutic predictive applications thereof
WO2019028131A1 (en) 2017-08-02 2019-02-07 Wake Forest University Health Sciences NICHES ON CHIP
US11629329B2 (en) 2017-10-11 2023-04-18 Wake Forest University Health Sciences Bioink compositions and methods of preparing and using the same
US12038432B2 (en) 2018-02-02 2024-07-16 Wake Forest University Health Sciences Organoids related to immunotherapy and methods of preparing and using the same
US11993785B2 (en) 2018-08-07 2024-05-28 Wake Forest University Health Sciences Immersion deposition methods and compositions for use in the same
US11213608B2 (en) 2018-08-14 2022-01-04 Wake Forest University Health Sciences Compositions including gelatin nanoparticles and methods of use thereof
US20220064597A1 (en) 2018-12-18 2022-03-03 Beth Israel Deaconess Medical Center, Inc. Generation of organoid-primed T (opT) cells with memory phenotype

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519360A (ja) 2010-02-11 2013-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ３ｄａｄｃｃｎｋｆａｃｓアッセイ

Also Published As

Publication number Publication date
JP2025172735A (ja) 2025-11-26
KR20200116944A (ko) 2020-10-13
JP2021511790A (ja) 2021-05-13
WO2019152767A1 (en) 2019-08-08
JP2023139153A (ja) 2023-10-03
US12038432B2 (en) 2024-07-16
EP3746785A1 (en) 2020-12-09
US20200363402A1 (en) 2020-11-19
US20240329034A1 (en) 2024-10-03
EP3746785A4 (en) 2022-05-11
KR102820005B1 (ko) 2025-06-12
AU2019215096A1 (en) 2020-08-06
CA3089127A1 (en) 2019-08-08
AU2019215096B2 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
JP7763450B2 (ja) 免疫療法に関するオルガノイドならびにそれを調製および使用する方法
AU2024204173B2 (en) Compositions, cell constructs, and methods of making and using the same
US20240192194A1 (en) Cancer modeling platforms and methods of using the same
Miserocchi et al. Management and potentialities of primary cancer cultures in preclinical and translational studies
US20240344005A1 (en) Devices, systems and methods for inhibiting invasion and metastases of cancer
CN114410466A (zh) 用于个性化癌症治疗的精确药物筛选
Greissinger Advancing T Cell Mediated Therapy Using 3D Tumor Organoids and Microfluidics
CN119677867A (zh) 用于使用微有机球测试肝细胞毒性的方法和装置
KR20250154508A (ko) 미세유기구에서의 세포 표지 및 주석
CN120958119A (zh) 将组分递送到微器官球的方法
HK40074891A (en) Precision drug screening for personalized cancer therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230808

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230831

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251015

R150 Certificate of patent or registration of utility model

Ref document number: 7763450

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150